Research directory

Clinical trials

Find trials by company, ticker, title or NCT ID.

Filters
Reset
1,647 trials match your filters.
TrialSponsorPhaseStatusPrimary completion
A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney DiseaseNCT02836574ProkidneyPhase 2Completed2023-12Actual
Study of PRO 140 SC as Single Agent Maintenance Therapy in Virally Suppressed Subjects With CCR5-tropic HIV-1 InfectionNCT02859961CytoDyn, Inc.Phase 2, Phase 3Completed2020-09-16Actual
Dociparstat Sodium (CX-01) Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid LeukemiaNCT02873338Jazz PharmaceuticalsPhase 2Completed2019-06Actual
Humacyte's HAV for Femoro-Popliteal Bypass in Patients With PADNCT02887859HUMAPhase 2Completed2020-12Actual
Safety and Efficacy Study of PTG-100 in the Treatment of Moderate to Severe Ulcerative ColitisNCT02895100PTGXPhase 2Terminated2018-03-26Actual
Setmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Deficiency ObesityNCT02896192RYTMPhase 3Completed2020-05-25Actual
Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)NCT02912260MDGLPhase 2Completed2017-10-25Actual
Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's DiseaseNCT02914561LKFTPhase 3Completed2022-11-11Actual
Filgotinib in Long-Term Extension Study of Adults With Crohn's DiseaseNCT02914600LKFTPhase 3Terminated2023-08-01Actual
Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Peanut AllergyNCT02920021ANABPhase 2Completed2018-03-30Actual
A Study to Evaluate Efficacy and Safety of SAGE-547 in Participants With Severe Postpartum Depression (547-PPD-202B)NCT02942004SUPNPhase 3Completed2017-09-24Actual
A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C)NCT02942017SUPNPhase 3Completed2017-09-17Actual
Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in WaldenstromNCT02952508CLRBPhase 2Active not recruiting2026-06-22Estimated
Safety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient ChildrenNCT02968004OPKPhase 3Completed2019-08Actual
Study to Assess the Efficacy of VLY-686 in Relieving Symptoms of GastroparesisNCT02970968Vanda PharmaceuticalsPhase 2Completed2018-11Actual
Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)NCT02973789NovoCure GmbHPhase 3Completed2024-09-24Actual
An Extension Protocol for Subjects Who Successfully Completed PRO140_CD02 or PRO140_CD02_Open Label StudyNCT02990858CytoDyn, Inc.Phase 2, Phase 3Terminated2022-06Actual
A Dose Determination and Safety Study of X4P-001 (Mavorixafor) in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) SyndromeNCT03005327X4 PharmaceuticalsPhase 2Completed2022-06-16Actual
Humacyte Acellular Tissue Engineered Vessel (ATEV) in Patients With Vascular TraumaNCT03005418HUMAPhase 2, Phase 3Completed2023-09-19Actual
Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of ObesityNCT03013543RYTMPhase 2Completed2022-03-01Actual
QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder CancerNCT03022825IBRXPhase 2, Phase 3Active not recruiting2024-10-01Actual
Oral Ifetroban to Treat Aspirin Exacerbated Respiratory Disease (AERD)NCT03028350Cumberland PharmaceuticalsPhase 2Completed2023-04-25Actual
INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted InfectionsNCT03037164Cerus CorporationPhase 3Active not recruiting2026-07-31Estimated
Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)NCT03038022MDGLPhase 2Completed2018-01-15Actual
Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDDNCT03051256RLMDPhase 2Completed2019-07-30Actual
Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal TreatmentNCT03059992SCYXPhase 3Completed2023-08-25Actual
Safety and Efficacy Study of TNX-102 SL in Patients With Military-related PTSDNCT03062540Tonix Pharmaceuticals, Inc.Phase 3Terminated2018-07-27Actual
Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal MelanomaNCT03070392Immunocore LtdPhase 2Completed2020-10-13Actual
Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & NeckNCT03083873IOVAPhase 2Completed2022-08-08Actual
ABX464 in Subjects With Moderate to Severe Active Ulcerative ColitisNCT03093259ABVXPhase 2Completed2018-07-25Actual

Primary completion marks the end of data collection for the main study measures, not a results publication date.